Treatment of systemic sclerosis

Area of Science:

• Rheumatology
• Clinical Research Methodology
• Systemic Sclerosis Research

Background:

• Growing concerns regarding the design and standards of clinical trials for systemic sclerosis.
• Need for improved disease activity markers and outcome measures for organ involvement (heart, lung, GI tract).

Purpose of the Study:

• To address challenges in systemic sclerosis clinical research.
• To highlight recent therapeutic trial findings and the need for standardized research approaches.

Main Methods:

• Review of recent clinical research experiences and published studies.
• Discussion of therapeutic agents like D-penicillamine, photopheresis, prokinetic drugs, and prostaglandins.
• Emphasis on the development of multicenter studies and uniform disease activity standards.

Main Results:

• Photopheresis showed benefit over D-penicillamine in a multicenter study.
• New prokinetic drugs show promise for gastrointestinal manifestations.
• Intravenous prostaglandins remain beneficial for Raynaud's phenomenon and digital ulcers, but oral prostaglandins were disappointing.

Conclusions:

• Clinical researchers are collaborating to design new multicenter studies.
• Establishing uniform standards for disease activity is crucial for determining appropriate treatments for systemic sclerosis.